McDermott Advises Meiogenix on its USD 13 million Series A Financing Round
McDermott Will & Emery advised Meiogenix on the closing of a USD 13 million (EUR 11 million) Series A financing round led by Sofinnova Partners, participated in by Genoa Ventures, Bpifrance, Casdin Capital and Alexandria Venture Investments.
Meiogenix is an agriculture biotech company which uses chromosome editing to expand genetic diversity in food and agriculture.
The Meiogenix platform hones in on the USD 50 billion commercial seed market, and in particular on essential crops like corn, wheat, rice, soybeans and tomatoes.
The McDermott team that advised Meiogenix comprised:
Anthony Paronneau (partner) and Laetitia de Dinechin, Ludivine Rabreau and Pascaline Sagot (associates).
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.